Fractyl Health, Inc. (GUTS) Stock Price & Analysis
Fractyl Health, Inc. (GUTS) closed at USD 4.16 on Thursday, October 15, 2026, up 1.96% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.08; the Oct 15, 2026 session ranged USD 3.92–4.21 on volume of 99,569 shares. Market capitalization is $55.18M, with a 52-week range of USD 3.78–29.34 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GUTS.md
Key facts (GUTS)
- 1 of 80 tracked superinvestors hold GUTS (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.14 on a 1–5 scale) (7 analysts), mean target USD 60.4 (range 24–96).
- Total return with dividends: 1Y -72.7% vs S&P 500 +18.1%; 5Y -97.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -1.5, revenue estimate $0K.
Superinvestors (SEC 13F-HR, Q2 2026) (GUTS)
1 of 80 tracked investors hold GUTS. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.03% | $3.2M | Unchanged |
Analysts (GUTS)
Consensus Buy (mean 2.14 on a 1–5 scale), 7 analysts; mean target USD 60.4 (low 24, high 96).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-01 | Craig-Hallum | Initiated | Buy | $4 |
Total return (dividends reinvested) (GUTS)
| 1Y (from 2025-10-16) | 5Y (from 2024-01-29) | |
|---|---|---|
| Total return | -72.7% | -97.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -72.8% | -73.6% |
| Volatility (annualized) | 145.8% | 135.4% |
| Max drawdown | -85.8% (Dec 2025→Oct 2026) | -97.3% (Jan 2024→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 4.16 |
|---|---|
| Change | ▲ 1.96% (up) |
| Previous Close | USD 4.08 |
| Open | USD 4 |
| Day Range | USD 3.92 – 4.21 |
| 52-Week Range | USD 3.78 – 29.34 |
| Volume | 99,569 shares |
| Market Cap | $55.18M |
| Exchange | NGM |
Technical Analysis (GUTS)
Nexqual's technical model rates GUTS "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.41 (oversold) |
| vs SMA50 | Below (USD 7.02) |
| MACD | -0.89 (negative) |
Analyst Ratings (GUTS)
Wall Street analysts rate GUTS "Buy" based on 7 analysts, with a mean price target of USD 60.4 (range USD 24–96), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 60.4 |
| High Target | USD 96 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (GUTS)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -1.5 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.41 vs est -1.64 ▲ beat |
| 2026-03-31 | USD -1.53 vs est -1.92 ▲ beat |
| 2025-12-31 | USD -0.84 vs est -2.16 ▲ beat |
| 2025-09-30 | USD -8.52 vs est -3.79 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (GUTS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 3.15 |
| Total Cash | $47.14M |
| Total Debt | $60.74M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (GUTS)
Nexqual rates Fractyl Health, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $47M cash vs $61M debt |
| Cash Flow | Weak — Operating cash flow -$90M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (GUTS)
| Insider Ownership | +1.45% |
|---|---|
| Institutional Ownership | +53.18% |
| Shares Outstanding | 13.26M |
| Float | 12.14M |
| Short % of Float | +1.44% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (GUTS)
Fractyl Health, Inc. is led by Harith Rajagopalan (age 48), Co-Founder, CEO, Director & Principal Executive Officer, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, CEO, Director & Principal Executive Officer | Harith Rajagopalan (age 48) |
|---|---|
| Co-Founder, Chief Product Officer & President | Jay D. Caplan BSEE (age 63) |
| CFO & Treasurer | Lara Smith Weber (age 50) |
| Senior Vice President of Regulatory, Quality & Clinical | Jon Fitzgerald |
| Senior Vice President of Market Access & Commercial Strategy | Mike Zumdahl |
Major Backers & Investors (GUTS)
Notable institutional backers of Fractyl Health, Inc. include Nantahala Capital Management, LLC, Catalio Capital Management, LP , Bank of America Corporation, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 0.59% |
| Catalio Capital Management, LP | 0.32% |
| Bank of America Corporation | 0.32% |
| Pale Fire Capital SE | 0.26% |
| General Catalyst Group Management, LLC | 0.26% |
| Deer Management Co. LLC | 0.25% |
| Maverick Capital Ltd. | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.63% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt